BMI vs SRAD

The Advanced Deterministic Scorecard shows a weak Piotroski F-Score of 4/9, indicating marginal financial health, and the absence of an Altman Z-Score prevents a full solvency risk assessment. Despite solid profitability metrics like 21.45% ROE and 19.57% operating margin, elevated valuation (P/E of 36.77 vs. sector average of 84.87) and bearish technical trend (0/100) offset strength in fundamentals. Revenue and earnings growth remain positive at 13.1% and 10.2% YoY, but recent price performance is sharply negative (-22% over 1Y), and analyst target suggests upside to $211.30. The stock trades well above the Graham Number of $49.73, reflecting premium pricing for growth expectations despite mixed earnings surprise trends.

SRAD exhibits a significant divergence between deterministic value metrics and growth expectations. The Piotroski F-Score of 4/9 indicates stable but mediocre financial health, while the Graham Number ($5.5) and Intrinsic Value ($2.59) suggest the current price of $17.42 is heavily overvalued by traditional standards. However, the company maintains a very clean balance sheet with a Debt/Equity ratio of 0.06 and consistent revenue growth of 20.1%. The stock is currently a speculative growth play, supported by a strong analyst consensus despite a bearish technical trend.